Scientists have created the first viable alternative to antibiotics, marking the next step in the fight against drug-resistant superbugs Scientists have created the first viable alternative to antibiotics, marking the next step in the fight against drug-resistant superbugs. A small test study has found the new drug is effective at targeting the bacteria that causes MRSA. Researchers believe the likelihood of the bug developing a resistance to the new drug is 'very limited'. A version of the drug is already used in specialist creams to treat conditions including acne, eczema, rosacea and skin irritations. Dutch biotech firm Micreos claims Staphefekt is the first endolysin - a bacteria-killing enzyme - available for use on human skin.
@highlight
A small test study found Staphefekt is effective in targeting MRSA
@highlight
Scientists believe likelihood  the bug will become resistant to the new drug is 'very limited', prompting them to hail the discovery a breakthrough
@highlight
Drug is already used in creams to combat skin conditions including eczema
@highlight
Targets bacteria resistant to antibiotics but leaves 'good' strains alone
@highlight
Britain's chief medical officer has said the threat posed by antibiotic resistant strains of bacteria is 'as bad as terrorism'
The firm is to conduct clinical trials of @placeholder and is looking to expand them internationally.